Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data
Thomas W Flaig, Ravi C Potluri, Yvette Ng, Mary B Todd, Maneesha Mehra, Thomas W Flaig, Ravi C Potluri, Yvette Ng, Mary B Todd, Maneesha Mehra
Abstract
Despite increasing drug treatment options for metastatic castration-resistant prostate cancer (mCRPC) patients, real-world treatment data are lacking. We conducted retrospective analyses of commercial claims and electronic medical record (EMR) databases to understand how treatment patterns for mCRPC have changed in a US-based real-world population. Truven Health Analytics MarketScan(®) (2000-2013) and EMR (2004-2013) databases were used to identify patients with an index prostate cancer diagnosis (ICD-9 codes 185X or 233.4X) and prescription claims for an mCRPC drug (mitoxantrone, estramustine, docetaxel, sipuleucel-T, cabazitaxel, abiraterone acetate, enzalutamide, or radium-223). Regimen analyses for first line of therapy (LOT1), second line of therapy, and beyond were performed among cohorts based on year of first mCRPC drug usage. mCRPC drug usage and treatment duration were compared across cohorts and age groups within each cohort. The commercial claims cohort yielded 3437 evaluable patients. Most men (91%) commencing mCRPC treatment had docetaxel as LOT1 in 2010; this number had declined to 15% in 2013. In 2013, 67% and 9% of patients used abiraterone acetate and enzalutamide, respectively, as LOT1. Among both commercial claims and EMR cohorts, treatment pattern changes were most pronounced in men aged >80 years, and median treatment duration for some mCRPC drugs was shorter than expected based on available clinical trial information. These results demonstrate a shift in mCRPC treatments during the past 5 years, with greater use of newer noncytotoxic treatments than docetaxel. These real-world data aid in understanding the changing role of chemotherapy in the management of mCRPC.
Keywords: metastatic castration-resistant prostate cancer; prostate cancer; real-world; treatment patterns.
© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Figures
References
- Garnick, M. B. , Glode L. M., Smith J. A. Jr, and Max D. T.. 1985. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate. Br. J. Clin. Pract. 39:73–76.
- Oudard, S. 2013. Progress in emerging therapies for advanced prostate cancer. Cancer Treat. Rev. 39:275–289.
- Lam, J. S. , Leppert J. T., Vemulapalli S. N., Shvarts O., and Belldegrun A. S.. 2006. Secondary hormonal therapy for advanced prostate cancer. J. Urol. 175:27–34.
- Tannock, I. F. , Osoba D., Stockler M. R., Ernst D. S., Neville A. J., Moore M. J., et al. 1996. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone‐resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14:1756–1764.
- Petrylak, D. P. , Tangen C. M., Hussain M. H., Lara P. N. Jr, Jones J. A., Taplin M. E., et al. 2004. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351:1513–1520.
- Tannock, I. F. , de Wit R., Berry W. R., Horti J., Pluzanska A., Chi K. N., et al. 2004. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351:1502–1512.
- Harris, V. , Lloyd K., Forsey S., Rogers P., Roche M., and Parker C.. 2011. A population‐based study of prostate cancer chemotherapy. Clin. Oncol. (R. Coll. Radiol.) 23:706–708.
- Droz, J. P. , Aapro M., Balducci L., Boyle H., Van den Broeck T., Cathcart P., et al. 2014. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 15:e404–e414.
- Fizazi, K. S. , Higano C. S., Nelson J. B., Gleave M., Miller K., and Morris T.. 2013. Phase III, randomized, placebo‐controlled study of docetaxel in combination with zibotentan in patients with metastatic castration‐resistant prostate cancer. J. Clin. Oncol. 31:1740–1747.
- Tannock, I. F. , Fizazi K., Ivanov S., Karlsson C. T., Flechon A., Skoneczna I., et al. 2013. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration‐resistant prostate cancer (VENICE): a phase 3, double‐blind randomised trial. Lancet Oncol. 14:760–768.
- Cookson, M. S. , Roth B. J., Dahm P., Engstrom C., Freedland S. J., Hussain M., et al. 2013. Castration‐resistant prostate cancer: AUA Guideline. J. Urol. 190:429–438.
- Kantoff, P. W. , Higano C. S., Shore N. D., Berger E. R., Small E. J., Penson D. F., et al. 2010. Sipuleucel‐T immunotherapy for castration‐resistant prostate cancer. N. Engl. J. Med. 363:411–422.
- de Bono, J. S. , Oudard S., Ozguroglu M., Hansen S., Machiels J. P., Kocak I., et al. 2010. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration‐resistant prostate cancer progressing after docetaxel treatment: a randomised open‐label trial. Lancet 376:1147–1154.
- Parker, C. , Nilsson S., Heinrich D., Helle S. I., O'Sullivan J. M., Fossa S. D., et al. 2013. Alpha emitter radium‐223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369:213–223.
- Montgomery, R. B. , Mostaghel E. A., Vessella R., Hess D. L., Kalhorn T. F., Higano C. S., et al. 2008. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration‐resistant tumor growth. Cancer Res. 68:4447–4454.
- O'Donnell, A. , Judson I., Dowsett M., Raynaud F., Dearnaley D., Mason M., et al. 2004. Hormonal impact of the 17alpha‐hydroxylase/C(17,20)‐lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 90:2317–2325.
- Tran, C. , Ouk S., Clegg N. J., Chen Y., Watson P. A., Arora V., et al. 2009. Development of a second‐generation antiandrogen for treatment of advanced prostate cancer. Science 324:787–790.
- Lissbrant, I. F. , Garmo H., Widmark A., and Stattin P.. 2013. Population‐based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 52:1593–1601.
- de Bono, J. S. , Logothetis C. J., Molina A., Fizazi K., North S., Chu L., et al. 2011. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364:1995–2005.
- Scher, H. I. , Fizazi K., Saad F., Taplin M. E., Sternberg C. N., Miller K., et al. 2012. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367:1187–1197.
- Rathkopf, D. E. , Smith M. R., de Bono J. S., Logothetis C. J., Shore N. D., de Souza P., et al. 2014. Updated interim efficacy analysis and long‐term safety of abiraterone acetate in metastatic castration‐resistant prostate cancer patients without prior chemotherapy (COU‐AA‐302). Eur. Urol. 66:815–825.
- Shelke, A. R. , and Mohile S. G.. 2011. Treating prostate cancer in elderly men: how does aging affect the outcome? Curr. Treat. Options Oncol. 12:263–275.
- Mulders, P. F. , Molina A., Marberger M., Saad F., Higano C. S., Chi K. N., et al. 2013. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration‐resistant prostate cancer after docetaxel‐based chemotherapy. Eur. Urol. 65:875–883.
- Mukherji, D. , Pezaro C. J., Shamseddine A., and de Bono J. S.. 2013. New treatment developments applied to elderly patients with advanced prostate cancer. Cancer Treat. Rev. 39:578–583.
- Fritz, J. M. , and Cleland J.. 2003. Effectiveness versus efficacy: more than a debate over language. J. Orthop. Sports Phys. Ther. 33:163–165.
- Revicki, D. A. , and Frank L.. 1999. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 15:423–434.
- Fizazi, K. , Scher H. I., Molina A., Logothetis C. J., Chi K. N., Jones R. J., et al. 2012. Abiraterone acetate for treatment of metastatic castration‐resistant prostate cancer: final overall survival analysis of the COU‐AA‐301 randomised, double‐blind, placebo‐controlled phase 3 study. Lancet Oncol. 13:983–992.
- Ryan, C. J. , Smith M. R., de Bono J. S., Molina A., Logothetis C. J., de Souza P., et al. 2013. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368:138–148.
- Beer, T. M. , Armstrong A. J., Rathkopf D. E., Loriot Y., Sternberg C. N., Higano C. S., et al. 2014. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371:424–433.
- National Comprehensive Cancer Network . 2016. NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline®): Prostate Cancer: Version 1. National Comprehensive Cancer Network Web site 2015 November 10; Available at . (accessed 30 November 2015).
Source: PubMed